Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 4NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Adenocarcinoma 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Has results × Medroxyprogesterone Acetate × Clear all
NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

GOG Foundation

Phase 2 Completed
74 enrolled 13 charts
Gynecologic

Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡